



DEPARTMENT OF THE AIR FORCE
59TH MEDICAL WING (AETC)
JOINT BASE SAN ANTONIO - LACKLAND TEXAS

3 MAR 2017

MEMORANDUM FOR SGVU
ATTN: JOSHUA CALCOTE

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled 59th Medical Wing Clinical Research Division Clinical Investigations Program Posters (Count: 16 of Varying Topics) presented at/published to Hanging in the Hallways at the 59th Medical Wing Clinical Research Division, Bldg 4430 in accordance with MDWI 41-108, has been approved and assigned local file #17110.
2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are 59 MDW staff member, we can forward your request for funds to the designated wing POC.
4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

Linda Steel-Goodwin

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP) ; Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
4. Attach a copy of your abstract, paper, poster and other supporting documentation.
5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). **This should be accomplished no later than 30 days before final clearance is required to publish/present your materials.** If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, *Presentation and Publication of Medical and Technical Papers*, for additional information.
11. The Joint Ethics Regulation (JER) DoD 5500.07-R, *Standards of Conduct*, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. **If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review.** To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP :

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS			
1. TO: CLINICAL RESEARCH	2. FROM: (Author's Name, Rank, Grade, Office Symbol) Calcote, Joshua - Contractor, 59 MDW/SGVU	3. GME/GHSE STUDENT: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO	4. PROTOCOL NUMBER: N/A
5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.) N/A			
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED: 59th Medical Wing Clinical Research Division Clinical Investigations Program Posters (Count: 16 of varying topics)			
7. FUNDING RECEIVED FOR THIS STUDY? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO FUNDING SOURCE:			
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
9. IS THIS MATERIAL CLASSIFIED? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.			
11. MATERIAL IS FOR: <input checked="" type="checkbox"/> DOMESTIC RELEASE <input type="checkbox"/> FOREIGN RELEASE CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED.			
<input type="checkbox"/> 11a. PUBLICATION/JOURNAL (List intended publication/journal.)			
<input type="checkbox"/> 11b. PUBLISHED ABSTRACT (List intended journal.)			
<input checked="" type="checkbox"/> 11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.) For hanging in the hallways of the 59th Medical Wing Clinical Research Division, Bldg 4430			
<input type="checkbox"/> 11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meeting.)			
<input type="checkbox"/> 11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)			
12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO ASSIGNED FILE # _____ DATE _____			
13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC). DATE N/A			
14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email) Calcote, Joshua C. - joshua.c.calcote.ctr@mail.mil			15. DUTY PHONE/PAGER NUMBER 210-292-7143
16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript.			
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/OFFICE SYMBOL	INSTITUTION (if not 59 MDW)
a. Primary/Corresponding Author Joshua C. Calcote	Contractor	59 MDW/SGVU	
b.			
c.			
d.			
e.			
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? <input type="checkbox"/> YES <input checked="" type="checkbox"/> NO			
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.			
18. AUTHOR'S PRINTED NAME, RANK, GRADE Dr. Joshua C. Calcote, Contractor		19. AUTHOR'S SIGNATURE <small>Digitally signed by JOSHUA C. CALCOTE, DN: cn=JOSHUA C. CALCOTE, o=59 MDW, ou=59 MDW, email=joshua.c.calcote.ctr@mail.mil, c=US</small>	20. DATE February 22, 2017
21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE Dr. Earl Grant, Jr., GS-14, DAF		22. APPROVING AUTHORITY'S SIGNATURE GRANT.EARL.JR.1126544380 <small>Digitally signed by EARL J. GRANT, DN: cn=EARL J. GRANT, o=59 MDW, ou=59 MDW, email=earl.j.grant@59mdw.af.mil, c=US</small>	23. DATE February 23, 2017

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS		
1st ENDORSEMENT (59 MDW/SGVU Use Only)		
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.	24. DATE RECEIVED February 23, 2017	25. ASSIGNED PROCESSING REQUEST FILE NUMBER 17110
26. DATE REVIEWED 27 Feb 2017	27. DATE FORWARDED TO 502 ISG/JAC	
28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: <input checked="" type="checkbox"/> NO <input type="checkbox"/> YES If yes, give date. <input type="checkbox"/> N/A		
29. COMMENTS <input checked="" type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED The posters are approved.		
30. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Rocky Calcote, PhD, Clinical Research Administrator	31. REVIEWER SIGNATURE CALCOTE.ROCKY.D.1178245844 <small>Digitally signed by CALCOTE ROCKY D 1178245844 DN: cn=US, o=U.S. Government, ou=DO, ou=PEL, ou=USAF, email=CALCOTE.ROCKY.D.1178245844 Date: 2017.02.27 14:06:47 -0500</small>	32. DATE
2nd ENDORSEMENT (502 ISG/JAC Use Only)		
33. DATE RECEIVED	34. DATE FORWARDED TO 59 MDW/PA	
35. COMMENTS <input type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED		
36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	37. REVIEWER SIGNATURE	38. DATE
3rd ENDORSEMENT (59 MDW/PA Use Only)		
39. DATE RECEIVED February 27, 2017	40. DATE FORWARDED TO 59 MDW/SGVU March 02, 2017	
41. COMMENTS <input checked="" type="checkbox"/> APPROVED (In compliance with security and policy review directives.) <input type="checkbox"/> DISAPPROVED		
42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER Kevin Iinuma, SSgt/E-5, 59 MDW Public Affairs	43. REVIEWER SIGNATURE IINUMA.KEVIN.MITSUGU.1296227 613 <small>Digitally signed by IINUMA KEVIN MITSUGU 1296227613 DN: cn=US, o=U.S. Government, ou=DO, ou=PEL, ou=USAF, email=IINUMA.KEVIN.MITSUGU.1296227613 Date: 2017.03.02 11:01:31 -0500</small>	44. DATE March 02, 2017
4th ENDORSEMENT (59 MDW/SGVU Use Only)		
45. DATE RECEIVED	46. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROVAL OR DISAPPROVAL <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> COULD NOT BE REACHED <input type="checkbox"/> LEFT MESSAGE	
47. COMMENTS <input type="checkbox"/> APPROVED <input type="checkbox"/> DISAPPROVED		
48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	49. REVIEWER SIGNATURE	50. DATE



59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SUPPORTED RESEARCH



"Non-Human Research Subject Blood Donor Initiative" – PI: Linda Harris – Author: Erica Dean

The Non-Human Research Subject Blood Donor Initiative, designed by the CRD, resulted in a significant reduction in the number of animals required to support trauma-related protocols. Use of this protocol in other Clinical Investigations Facilities could drastically reduce the number of animals required to support trauma- and resuscitation-focused research.



"Use of Miniature Marshmallows to Reduce Stress, Enhance Safety, and Increase Efficiency When Working With Sinclair Miniature Swine"


– PI: Linda Harris – Author: Erica Dean

Sinclair Miniature Swine familiar with people and mini-marshmallows are easily trained to perform simple husbandry behaviors such as standing still or walking from one cage to another. These behaviors minimize the need for physical handling thereby reducing stress, decreasing procedure time, and enhancing safety.




"The Frequency of Fungal Culture Contamination in Normal Toenails versus Periodic Acid Schiff (PAS) and Gomori's Methenamine Silver (GMS) Stains in the Diagnosis of Onychomycosis" – PI: Shannon McCann

Onychomycosis is a common worldwide problem identified in 14% of the population. This study used cultures and special stains of toenail clippings to determine if contamination of toenail samples (before collection) are being misinterpreted as Onychomycosis, if age relates to the level of contamination, and what are the organisms isolated in the clinically normal toenails.



"Tissue Sharing from the Aortic Balloon Occlusion and the Abdominal Aortic and Junctional Tourniquet in a Coagulopathic Model of Pelvic Hemorrhage in Swine Study" – PI: Matthew Wordsworth

The purpose of this study is to map the nerve and better understand the anatomy of the swine before establishing and conducting future nerve studies (the nerve innervation may vary from strain to strain).



"Efficacy of Intravenous cobinamide versus hydroxocobalamin or saline for treatment of severe hydrogen sulfide toxicity in a swine (*Sus Scrofa*) model" – PI: Maj Joseph Maddry

Hydrogen sulfide (H_2S) is a potentially deadly gas that naturally occurs in petroleum and natural gas. This study compared the time to spontaneous ventilation among groups of swine with acute H_2S -induced apnea treated with intravenous (IV) cobinamide, IV hydroxocobalamin, or saline. All of the cobinamide-treated animals survived, whereas, none of the control or hydroxocobalamin-treated animals survived.



"Brain Magnetic Resonance Imaging (MRI) and Neuropathological Effects of Hypobaric Exposure to 30,000 Feet and Hyperoxic Exposure at Sea Level in Miniature Swine" – PI: Col Paul Sherman

This study utilized miniature swine, a hypobaric chamber, and an MRI to safely and effectively demonstrate white matter injury (brain MRI changes) seen with high altitude (hypobaric) exposure in America's high altitude pilots and the observers who assist in the



59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES



Cell Biology & Immunology



Equipment:

- Dedicated BSL-2 Hoods
- Flow Cytometer
- Fluorescent Microscopy
- Confocal Microscopy
- Microdialysis Analysis
- Microplate Reader
- MagPix



Capabilities:

- Tissue Culture
- Proliferation-Viability
- Cell Stain
- Fluorescent Microscopy/Image Analysis
- Analysis of Brain/Kidney Microdialysate
- Single-Plex/Multiplex Biomarker Detection/Quantification
- Cell Marker Detection/Identification





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES





Microbiology

Equipment:

- VITEK Bacterial ID/Susceptibility System
- Aerobic/Anaerobic Incubators
- Laminar Flow Biological Safety Cabinet
- Bright Field Microscopy
- Electron Microscopy

Capabilities:

- Aerobic & Anaerobic Bacterial Cultures
- Bacterial ID and Susceptibility
- Bacterial Adhesion Studies
- Disinfectant Reliability Studies
- Epidemiology Studies
- Comparison of Conventional & New Clinical Microbiology Methodologies





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES




Molecular Biology

Equipment:

- Next Generation Sequencers
 - NextSeq 500
 - Personal Genome Machine (PGM)
- Automated Extractor
- PCR & RT-PCR
- Pyro Sequencing
- Sanger Sequencing
- Ultrasonicator
- Fragment Analyzer
- Microarray

Capabilities:

- Nucleic Acid Sequencing
 - Full Genome
 - Exome
 - Transcriptome
 - Multiplex-Targeted
 - Microbiome
- Genotyping/SNP Detection
- Nucleic Acid Fragmentation
- Nucleic Acid Quantification and Quality Assessment





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES





Hematology & Hemostasis

Equipment:

- CBC Analyzer (Human & Multispecies Capable)
- Coagulation Analyzers
 - STA-R Evolution Hemostasis System
 - Thromboelastograph Hemostasis Analyzers
 - ROTEM® Delta System

Capabilities:

- Complete Blood Count
- Platelet
- Reticulocyte
- Differential
- Routine/Specialty Coagulation Testing
 - PT/PTT/Fibrinogen
 - Clotting Time, Speed of Clot Formation, Clot Firmness






59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

LABORATORY BRANCH SUPPORT CAPABILITIES



Equipment:


- High/Ultra Performance Liquid Chromatography
- Photodiode Array Detectors
- Fluorescent Detectors
- Clinical Chemistry Analyzer
- pH/ISE/Conductivity Meter
- Three-Liquid Chromatographic Triple Quadrupole Mass Spectrometers
- Two-Gas Chromatographic Mass Specs
- Solid Phase Extraction System



Chemistry / Toxicology

Capabilities:

- Drug and Drug Metabolites
- Natural Product Chemistry
- Disease Predictors
- Medical Readiness Research
- Full range of Clinical Chemistry analyses on Various Sample Types
- High Sensitivity pH and Ion Monitoring
- Therapeutic Drug/Immune Suppressants
- Analgesics in Pain Management
- Toxic Compounds and Allergens





59th Medical Wing Clinical Research Division

Methylation Status of Genes via Pyrosequencing

Supported Project:

Supported Project:

- Adverse childhood experience and serotonin transporters: a gene environmental interaction study of the risk of PTSD in soldiers (ACES)"



Principal Investigator:

Capt Michael R. Hossack, MD

CRD Laboratory Support Staff:

Dr. Thomas Gibbons
Mr. Leo Longoria
Dr. Jody Noe
Mr. Richard LaBoone

CRD Support: GME investigators requested lab support to assess the methylation status of genes. After consulting with CRD Lab Scientist, Investigators decide to utilize Pyrosequencing for their Protocol.



Sample ID	Well	Assay	ID	Internal Control (IT)	Internal Control (IC)	%subliffe conversion of control	Mean	Min	Max	SD
Low Cont	A5	BDNF 08	L	150.12	6.32	4%	3%	3%	4%	0%
	A5	BDNF 10	L	192.94	9.38	5%	3%	5%	8%	2%
	A1	NR3C1 01	L	363.37	7.38	2%	4%	3%	6%	1%
	B5	NR3C1 05	L	220.15	3.55	3%	3%	1%	5%	2%
	C5	NR3C1 05	L	218.72	4.11	4%	4%	2%	8%	2%
High Cont	A6	BDNF 08	H	138.44	6.38	3%	96%	95%	98%	1%
	A6	BDNF 10	H	111.60	8%	95%	95%	90%	100%	4%
	A2	NR3C1 01	H	425.86	9.96	2%	92%	75%	98%	9%
	B6	NR3C1 05	H	219.40	5.29	5%	89%	79%	93%	7%
	C6	NR3C1 05	H	140.63	1.36	2%	90%	77%	97%	9%
P140011	A7	BDNF 08	11	230.08	6.08	3%	5%	4%	6%	1%
	A7	BDNF 10	11	203.04	6.73	3%	6%	4%	11%	3%
	A3	NR3C1 01	11	480.56	7.76	2%	4%	2%	6%	2%
	B7	NR3C1 05	11	151.78	1.92	2%	3%	2%	6%	5%

A. Development:

- . Selecting regions of Genome
- . Selecting/Designing of Primers
- . Verification of Assays

B. Performance:

- Collect & Extract DNA from Sample
- Bisulfite Conversion of DNA
- PCR Converted DNA
- Pyrosequence

C. Dissemination:

- Analyze/Interpret Data
- Provide Data in Excel Format
- Provide Materials & Methods for Publication of Research



59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH



Image Analysis via Laser Scanning Confocal Microscopy (LSCM)

Supported Projects:


"MYC and BCL-2 Double Immunohistochemistry on Diffuse large B Cell Lymphoma" – PI: Maj Jean Coviello CRD Laboratory Support Staff: Ms. Lori Heinrichs, Ms. Sally Banfield, and Dr. Thomas Gibbons
"Expression of odorant receptors in non-olfactory neurons to induce selective axonal fasciculation" – PI: Maj Travis Newberry CRD Laboratory Support Staff: Ms. Patti Dixon and Dr. Thomas Gibbons

CRD Support: GME investigators request lab support to assess chromosomal abnormalities via FISH, abnormal protein production via IHC, and directed nerve innervation in tissue culture.




A. Development:

- Coordinate with CRD Histology for FFPE
- Selecting FISH Probes
- Selecting Primary/Secondary Antibodies
- Optimization/Verification of Assays



B. Performance:

- Prepare Samples
- Stain Samples
- Image



C. Dissemination:

- Deliver Stained Slides to PI
- Analyze/Interpret Data
- Provide Materials & Methods for Publication of Research



59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM



SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH

“Saving the Unsurvivable with En Route Extracorporeal Membrane Oxygenation (ECMO)”


Principal Investigator:
Maj Joseph Maddry, MD

Associate Investigators:
Lt Col Phillip Mason
Capt James Lantry
Normalynn Garrett
Shelia Savell, PhD, RN

Description:

This study will develop and provide an accelerated ECMO course to Military Critical Care Clinicians (MCCC) subjects and, subsequently, determine their ability to place ECMO intravascular catheters, initiate ECMO therapy in an ECMO patient, and troubleshoot common ECMO complications with and without teleconsultative support during transport of ECMO patients.

CRD Support: surgical suites; swine models; surgical technicians; pre/post-surgical care; animal housing; laboratory support





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH

“Evaluation of Prehospital Uncontrolled Hemorrhage and Use of Medical Adjunct Therapies”



Principal Investigator:
Jason Rail, PhD

Associate Investigators:
Capt Kai Hata, MD
Ed Chagoy
Jennifer Cox

Problem: Hemorrhage is associated with greater than 90% of potentially survivable deaths on the battlefield. Survival from these injuries often leads to multiple organ failure and ischemic damage during evacuation to definitive medical care. Techniques for the control of hemorrhage and that protect patient vital organs during evacuation need to be improved.

This study is investigating if Selective Aortic Arch Perfusion (SAAP) can be used to treat both uncontrolled hemorrhage and be used to induce suspended animation by profound hypothermia. New and advanced SAAP mechanical components, pumps, catheters, and oxygenators will be tested for field use.

CRD Support: surgical suites; swine models; surgical technicians; fresh whole blood; pre/post-surgical care; animal housing; laboratory support





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH



“Comparison of the Efficacy of REBOA and AAJT in a Swine Model of Uncontrolled Pelvic Bleeding”

Principal Investigator:
Jason Rall, PhD

Associate Investigators:
Ed Chagoy
Jennifer Cox


Hypothesis:

This study will test whether the Abdominal Aortic and Junctional Tourniquet (AAJT) will be as effective as Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in achieving hemostasis in a swine model of pelvic hemorrhage and will determine the reperfusion injury produced by each treatment. AAJT application requires less time and skill than REBOA.

Military Relevance:

Hemorrhage due to injuries to the pelvis and junctional areas remains a difficult problem on the battlefield. Effective methodologies to stop hemorrhage from these areas are needed.

CRD Support: surgical suites; swine models; surgical technicians; pre/post-surgical care; animal housing; laboratory support





59th Medical Wing Clinical Research Division

CLINICAL INVESTIGATIONS PROGRAM

SPOTLIGHT ON GME/GHSE-SUPPORTED RESEARCH



“Brain Magnetic Resonance Imaging (MRI) and Neuropathological Effects of Hypobaric Exposure to 30,000ft and Hyperoxemic Exposure at Sea Level in a *Sus scrofa domestica* model”

Principal Investigator:
Col Paul Sherman, MD


Associate Investigators:
Capt P. Dana Peralla, MD
Lt Col John Sladky, MD
Stephen McGuire, MD

Description:

In a continuing effort to demonstrate white matter injury seen with hypobaric exposure in our high altitude pilots and aerospace physiology altitude chamber inside-observers, 36 swine in 3 limbs were exposed to pre-determined altitude and O₂ levels 6 times over 3 weeks and underwent 3 MRI scans each. Unlike previous studies, these swine are non-sedated and alert during exposure. Serologic analysis and necropsy with neuropathological evaluation were performed on each animal.

This study utilized miniature swine, a hypobaric chamber, and an MRI to safely and effectively demonstrate white matter injury (brain MRI changes) seen with high altitude (hypobaric) exposure in America's high altitude pilots and the observers who assist in the aerospace physiology chambers.

CRD Support: hypobaric chamber, specialized pre/post-flight animal cages; surgical suites; swine models; surgical technicians; pre/post-surgical care; pathology; laboratory support





Calculating IRB Review & Approval Turn-Around Times

As part of the effort to earn national accreditation through the Association for the Accreditation of Human Research Protection Programs (AAHRPP), the 59th Medical Wing (59 MDW) Institutional Review Board (IRB) tracks the time it takes for Research Protocols to be reviewed and approved (i.e., turn-around time). The 59 MDW IRB developed a unique data mining system allowing for the pin-pointing of bottle-necks in the review process. IRB Records are examined for important milestone dates (e.g., protocol submission date, Notice of Action date, etc.) and these data are put into a spreadsheet where various turn-around times are calculated. All data entries correspond to color-coded study review types or IRB actions (see chart below). Such data collection enables highly specific IRB, Expedited, and Exempt review process improvements.


Column heading snapshot of turn-around time calculation spreadsheet

[illegible]

EXAMPLE
Data Input Sheet
(mm/dd/yyyy)

EXAMPLE
Calculation Sheet
(in work-days)


TURN-AROUND TIME COMPARISON TO AAHRPP BENCHMARKS INCLUDING INVESTIGATOR TIME FOR CORRECTIONS TO PROTOCOL DOCUMENTS



COLOR-CODED CATEGORIES OF REVIEW AND IRB ACTIONS



TURN-AROUND TIME COMPARISON TO AAHRPP BENCHMARKS EXCLUDING INVESTIGATOR TIME FOR CORRECTIONS TO PROTOCOL DOCUMENTS





59th Medical Wing Clinical Research Division
CLINICAL INVESTIGATIONS PROGRAM
PUBLICATIONS AND PRESENTATIONS - FY2016

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------



59th Medical Wing Clinical Research Division

[illegible][illegible][illegible]



59th Medical Wing Clinical Research Division
CLINICAL INVESTIGATIONS PROGRAM
A SNAPSHOT OF OUR EXEMPT RESEARCH STUDIES

[illegible]